DK2217208T3 - Nucleinsyrekompleks og nucleinsyrefremføringssammensætning - Google Patents

Nucleinsyrekompleks og nucleinsyrefremføringssammensætning

Info

Publication number
DK2217208T3
DK2217208T3 DK08848047.0T DK08848047T DK2217208T3 DK 2217208 T3 DK2217208 T3 DK 2217208T3 DK 08848047 T DK08848047 T DK 08848047T DK 2217208 T3 DK2217208 T3 DK 2217208T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
feed composition
complex
acid complex
acid feed
Prior art date
Application number
DK08848047.0T
Other languages
English (en)
Inventor
Hirofumi Takeuchi
Yuichi Tozuka
Yasuyuki Hira
Hidekazu Toyobuku
Original Assignee
Otsuka Pharma Co Ltd
Hirofumi Takeuchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Hirofumi Takeuchi filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK2217208T3 publication Critical patent/DK2217208T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK08848047.0T 2007-11-08 2008-11-06 Nucleinsyrekompleks og nucleinsyrefremføringssammensætning DK2217208T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08
PCT/JP2008/070642 WO2009061003A2 (en) 2007-11-08 2008-11-06 Nucleic acid complex and nucleic acid delivery composition

Publications (1)

Publication Number Publication Date
DK2217208T3 true DK2217208T3 (da) 2011-10-10

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08848047.0T DK2217208T3 (da) 2007-11-08 2008-11-06 Nucleinsyrekompleks og nucleinsyrefremføringssammensætning

Country Status (27)

Country Link
US (1) US8338584B2 (da)
EP (1) EP2217208B1 (da)
JP (1) JP5340282B2 (da)
KR (1) KR101567108B1 (da)
CN (1) CN101854918B (da)
AR (1) AR069224A1 (da)
AT (1) ATE522201T1 (da)
AU (1) AU2008325504B2 (da)
BR (1) BRPI0819187A2 (da)
CA (1) CA2704236C (da)
CO (1) CO6280469A2 (da)
CY (1) CY1112029T1 (da)
DK (1) DK2217208T3 (da)
ES (1) ES2369869T3 (da)
HR (1) HRP20110698T1 (da)
IL (1) IL205237A0 (da)
MX (1) MX2010005094A (da)
MY (1) MY149917A (da)
NZ (1) NZ584841A (da)
PL (1) PL2217208T3 (da)
PT (1) PT2217208E (da)
RU (1) RU2465009C2 (da)
SI (1) SI2217208T1 (da)
TW (1) TWI426922B (da)
UA (1) UA97559C2 (da)
WO (1) WO2009061003A2 (da)
ZA (1) ZA201002845B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
ES2605990T3 (es) 2010-12-29 2017-03-17 F. Hoffmann-La Roche Ag Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
EP2825565B1 (en) 2012-03-15 2019-04-03 Aziende Chimiche Riunite Angelini Francesco A.C.R. Glycogen-based cationic polymers
WO2019131727A1 (ja) * 2017-12-27 2019-07-04 コニカミノルタ株式会社 医薬の評価方法
WO2025029927A1 (en) * 2023-07-31 2025-02-06 The Board Of Regents Of The University Of Texas System Lipid nanoparticle

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) * 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) * 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Hivコファクター抑制剤
DK1129064T3 (da) 1998-11-12 2008-04-28 Invitrogen Corp Transfektionsreagenser
EP1575976A4 (en) * 2001-11-02 2006-08-23 Insert Therapeutics Inc METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
WO2004042002A2 (en) * 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
TWI426922B (zh) 2014-02-21
JP5340282B2 (ja) 2013-11-13
HK1142278A1 (en) 2010-12-03
PL2217208T3 (pl) 2012-01-31
EP2217208A2 (en) 2010-08-18
CA2704236A1 (en) 2009-05-14
ES2369869T3 (es) 2011-12-07
MX2010005094A (es) 2010-05-27
JP2011504457A (ja) 2011-02-10
TW200927175A (en) 2009-07-01
RU2465009C2 (ru) 2012-10-27
SI2217208T1 (sl) 2011-11-30
CY1112029T1 (el) 2015-11-04
UA97559C2 (uk) 2012-02-27
CN101854918A (zh) 2010-10-06
EP2217208B1 (en) 2011-08-31
ZA201002845B (en) 2011-07-27
KR101567108B1 (ko) 2015-11-06
AR069224A1 (es) 2010-01-06
MY149917A (en) 2013-10-31
CN101854918B (zh) 2012-11-28
CO6280469A2 (es) 2011-05-20
CA2704236C (en) 2015-09-15
HRP20110698T1 (hr) 2011-10-31
KR20100092007A (ko) 2010-08-19
US20100305190A1 (en) 2010-12-02
IL205237A0 (en) 2010-11-30
WO2009061003A3 (en) 2010-05-27
PT2217208E (pt) 2011-11-08
US8338584B2 (en) 2012-12-25
RU2010123168A (ru) 2011-12-20
NZ584841A (en) 2011-12-22
BRPI0819187A2 (pt) 2015-05-05
AU2008325504B2 (en) 2013-03-07
AU2008325504A1 (en) 2009-05-14
ATE522201T1 (de) 2011-09-15
WO2009061003A2 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
DK1984502T3 (da) Nukleinsyre
GB0706243D0 (en) Modified nucleic acids
EP2201021A4 (en) METHOD OF ALTERNATING NUCLEIC ACID SEQUENCING
DK3338790T3 (da) Oligopeptid-forbindelser og anvendelser deraf
DK2129797T3 (da) Nukleinsyrepåvisning
GB0701253D0 (en) Nucleic acid amplification and testing
BRPI0820020A2 (pt) Material anticorrosão
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
DK2049671T3 (da) Regulatoriske nukleinsyreelementer
EP2126072A4 (en) MATERIALS AND METHOD FOR THE INDIVIDUAL MOLECULE SEQUENCING OF NUCLEIC ACIDS
EP2210268A4 (en) IN THE BIOSENSORS USED NEW CHEMISTRY
EP2203565A4 (en) ACETHYDROXYACID SYNTHASE GENES MUTATED AT BRASSICA
BRPI0909212A2 (pt) Composições e método para sequeciamento de ácido nucléico
BRPI0813775A2 (pt) Composição
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
ATE528048T1 (de) Schweisshemmende/desodorierende zusammensetzung
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
EP2123752A4 (en) NOVEL NUCLEIC ACID
EP2077326A4 (en) NOVEL NUCLEIC ACID
BRPI0810557A2 (pt) composição
EP2211171A4 (en) BIOSENSOR
PT2182988E (pt) Composição radiofarmacêutica
GB0812862D0 (en) Nucleic acid amplification
NO2022038I1 (no) ropeginterferon alfa-2b
BRPI0811002A2 (pt) Composição biofertilizante